513 results about "Treatment medication" patented technology

A device for treating cardiac disease of a heart having an upper portion and a lower portion divided by an A–V groove, the device including a jacket adapted to be secured to the heart, and a delivery source for the delivery of one or more therapeutic agents to the surface of the heart. The jacket is fabricated from a flexible material defining a volume between an upper and a lower end, the jacket being adapted to be adjusted on the heart to snugly conform to an external geometry of the heart and assume a maximum adjusted volume for the jacket to constrain expansion of the heart beyond the maximum adjusted volume during diastole and permit substantially unimpeded contraction of the heart during systole. As a result of the flexible material, the jacket allows unimpeded diastolic filling of the heart. Also described is a method for treating cardiac disease including surgically accessing the heart, applying the treatment device of the invention, securing the treatment device to the heart, and surgically closing access to the heart while leaving the treatment device on the heart.

A diagnostic tool is disclosed for accurately and rapidly diagnosing the condition of an ailing organ. Although applicable to numerous organ and organ systems, this application particularly illustrates the concept of conjunctive marker utilization as it relates to diagnosing and distinguishing congestive heart failure. The invention particularly relates to the conjunctive utilization of cardiac Troponin I (cTn-I) and natriuretic peptide, e.g. ANP, pro-ANP, BNP, pro-BNP and CNP as a retrospective tool for diagnosing the underlying mechanism of heart failure and as a prospective analytical device for monitoring disease progression and efficacy of therapeutic agents.

The object of the present invention is to discover a combination of preventive or therapeutic drugs for glaucoma or ocular hypertension, which is useful as a preventive or therapeutic agent for glaucoma or ocular hypertension. By combining isopropyl(6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate with other preventive or therapeutic drug for glaucoma or ocular hypertension, their intraocular pressure lowering effects are complemented and / or enhanced each other. As for the administration form, these drugs may be administered concomitantly or may be administered as a combination drug.

The present invention provides a filtration assembly in the form of a disposable cartridge. A key feature of the invention is a filtration chamber having a porous membrane also referred to as a filter, a sample inlet to the filtration chamber, and an outlet for outflow of the fraction of sample that does not penetrate the membrane. The membrane can be used in any configuration, for example a hollow fiber. The fraction of sample that penetrates the membrane is referred to as the filtrate, and the fraction that does not penetrate the membrane is referred to as the retentate or concentrate. Some uses of the cartridge are to prepare plasma from blood, and to prepare a plasma ultra-filtrate from plasma, without the need for centrifugation. Many therapeutic drugs are highly protein bound, and a plasma ultra-filtrate is sometimes required to measure the unbound biologically active drugs.

The invention discloses 2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl) acetic acid(I) and an optical isomer(II) thereof; and the invention also discloses a method for preparing the compound and the application of the compound in the preparation of ramelteon which is a medicament for treating insomnia.

The present invention provides a particulate composition wherein an oil component containing reduced coenzyme Q10 is polydispersed forming a domain in a matrix containing a water-soluble excipient, which simultaneously shows high oxidative stability and high oral absorbability, a production method thereof, and a stabilizing method thereof. It also provides a food, food with nutrient function claims, food for specified health uses, dietary supplement, nutritional product, animal drug, drink, feed, pet food, cosmetic, pharmaceutical product, therapeutic drug, prophylactic drug and the like, which contain the composition.

The invention discloses application of serine, which is used as a biological marker and has +79.96685 mass shift at a 208 site of AKAP3 (A-kinase Anchor Protein 3), to preparation of a diagnostic reagent or a treatment medicine of severe oligoasthenospermia. According to the application disclosed by the invention, the severe oligoasthenospermi can be diagnosed through testing frequency of the +79.96685 mass shift occurring at the 208 site of the AKAP3, and new diagnosis and new treatment target spots are provided for the severe oligoasthenospermia.

The present invention relates to radioactive magnetic fluids, process for preparing them and use thereof. Particularly, the present invention relates to the radioactive magnetic fluids for treatment or diagnosis of cancer, process for preparing them and use thereof. The radioactive magnetic fluids of the present invention include the component of Cu2+ which radiates a β-ray and γ-ray. The β radiation can effectively kill the tumor cells. Since the γ radiation are easily imaged with γ-camera, the magnetic fluids can be gathered to the treatment site with the radiograph under external magnetic field. Therefore, the radioactive magnetic fluids of the present invention can be used for treatment of cancer with minimal side effects. Also, the tightly bonded decanoic acid and nonanoic acid layer of the present invention not only increase particle-particle repulsion but also take hydrophilicity, to disperse homogeneously and stably the magnetic nanoparticles in water. Also, carboxylic acid of the surfactant is exposed to outside, to prevent the magnetic nanoparticles from being oxidized by air. Therefore, the radioactive magnetic fluids can be used as therapeutic drug or diagnostic reagent for cancer.

The invention discloses 2-(1,6,7,8-tetrahydrogen-2H-indeno-[5,4-b] furan-8-group) acetonitrile (I), an optical isomer (II) thereof, a preparation method of the compound and application of the compound in preparing ramelteon which is a medicament for treating insomnia.

The invention discloses a human anti-H7N9 avian influenza virus neutralizing antibody 1F7L screened by a single cell sorting technology. The amino acid sequences in the light and heavy chain variable regions are shown in the formulas of SEQ ID No. 2 and SEQ ID No. 5. The antibody has the ability to neutralize the H7N9 influenza viruses in vitro and mediates the killing (ADCC) of the H7N9 influenza virus-infected cells with effector cells mainly comprising NK cells. The antibody can be used as a treatment drug for highly pathogenic avian influenza infection and can also be used for the development of H7N9 influenza virus antigen detection reagents.

The invention provides a black phosphorus quantum dot composite material comprising a black phosphorus quantum dot, positive ions modified on the surface of the black phosphorus quantum dot and polyethylene glycol or polyethylene glycol derivatives. The positive ions comprise the metal positive ions or the ammonium ions. The positive ions are combined with the black phosphorus quantum dot through electrostatic force, and the pieces of polyethylene glycol or the polyethylene glycol derivatives are combined with the black phosphorus quantum dot through Van der Waals force. According to the black phosphorus quantum dot composite material, the positive ions are combined with the black phosphorus quantum dot through the electrostatic force, so that the oxidation resistance ability of the positive ions is improved greatly, and the pieces of polyethylene glycol or the polyethylene glycol derivatives are combined with the black phosphorus quantum dot through the Van der Waals force so that the black phosphorus quantum dot can be stably dispersed in water. The invention provides a preparation method of the black phosphorus quantum dot composite material in the second aspect. The method is simple and easy to operate. The black phosphorus quantum dot composite material can be used for preparing photoacoustic imaging drugs, or photothermal therapy drugs, or photodynamic therapy drugs or drug-loading targeted therapy drugs.

The invention discloses a small-size gold nanorod and a preparation method and applications thereof. The growth reaction is adjusted by utilization of cationic-anionic surfactants as a mixed growth template, and synthesis of the small-size gold nanorod with the diameter of 5-9 nm is achieved through the non-gold-seed one-step method. The diameter and the length-diameter ratio of the small-size gold nanorod are adjusted through changes of the mole ratio of the chloroauric acid to the cationic-anionic surfactants to the silver nitrate. Operation is simple, consumed time is short, repeatability is good, and the small-size gold nanorod good in monodispersity and uniform in size can be obtained with no ultrasound in the preparation process. The diameter of the small-size gold nanorod is 5-9 nm, the size is small, and the ratio of the absorption value of a longitudinal surface plasma resonance absorption peak to the absorption value of a transverse surface plasma resonance absorption peak of the small-size gold nanorod is 2.5-5.5. The prepared small-size gold nanorod can be applied to the fields of preparation of photo-thermal treatment drugs, optical mark drugs, sensors and the like.

The invention discloses a medication decision-making support method based on drug knowledge map reasoning. According to the method, a patient interaction module, a medication decision-making support module and the like are arranged. The patient interaction module is used for acquiring pathophysiological information by means of voice interaction and check interaction and the like, thereby providingassistance for a doctor for prescription. The medication decision-making support module includes a treatment medication recommendation sub module and a safety medication examination sub module. The treatment medication recommendation sub module recommends one or more kinds of drugs for the doctor for prescription preliminarily based on information including patient diseases, taboos, and allergensand being obtained by the patient interaction module as well as drug information in a drug knowledge map; and the safety medication examination sub module is used for carrying out examination based on the medication safety situation of the patient by the patient. According to the method, drug recommendation is provided automatically by using the drug knowledge map and the pathophysiological information of the patient; and the doctor is assisted in make prescription and the drugs based on the prescription is processed by safety examination. Therefore, the basic information acquisition time ofthe patient by the doctor is saved; the doctor's diagnosis and treatment efficiency is improved obviously; and the safety of clinical medication is enhanced.

The invention discloses a detecting method for accurate risk early warning and accurate drug use of cardiovascular and cerebrovascular diseases and a specific primer. The invention provides a specific primer for detecting SNP site of drug resistance of the cardiovascular and cerebrovascular diseases, which comprises a primer group 1 and a primer group 2; the primer group 1 is composed of primer pair 1-primer pair 13; a primer group 2 is composed of single stranded extended primer 1- single stranded extended primer 13; the method can efficiently detect and complete the accurate early warning of the attack of the cardiovascular and cerebrovascular diseases and the accurate drug use after being attacked, namely, four kinds of cardiovascular and cerebrovascular disease early warning with huge health risk and accurate drug use of four clinical common drugs (aspirin, nitroglycerin, warfarin, and clopidogrel) for prevention and treatment of cardiovascular and cerebrovascular diseases.

The present invention provides a method for fabricating an implant stent with therapeutic effects. The method of the present invention includes designing and delineating a pattern of the implant stent, drilling a thin metal sheet to form positioning holes, cutting a desired pattern on the thin metal sheet according to the designed pattern, drilling a hole on a line rib of the stent to form a braided structure by a micro discharge processor according to the desired pattern. Then, the stent is cleaned and polished by the electropolish to trim the edge and the rough surface of the stent. Then, the biodegradable material, PLLA, PGA, fibrinogen, the polyurethane-polyethylene oxide mixed with the heparin or the combination thereof, is used for forming the mixed material with the high molecular weight, and is solved in a solvent, wherein another grinded therapeutic drug with the micro or the nano size is added. The drug can be As2O5, an anti-caner drug, or an anti-inflammation drug. The solution with the bioadsordable material having a therapeutic drug is atomized and sprayed on the outer and inner surfaces of the stent. Since a row of holes are arranged on the line rib of the stent, each hole is immersed into the solution due to the capillary phenomenon. When the solution is completely evaporated, the biodegradable and absordable material and the drug are coagulated to form a solid and to strongly coat on the surface of the stent. When the stent is implanted into a human body, the solid layer is slowly degraded and released on the injured site, so that the vessel is prevented from restenosis, and the therapeutic effect is achieved. The stent can be fabricated by the precision machine technology in Taiwan, so that the implant stent with low cost and therapeutic effects is obtained.

The invention provides a liquid medicine atomizing drainage device and method. A liquid medicine storing and atomizing cavity, a gas compression pump, a high-pressure airflow channel, a high-pressure airflow nozzle, a liquid medicine absorbing pipe and a spacer; an atomizing opening is formed in the upper end of the liquid medicine storing and atomizing cavity and is connected with a corrugated pipe through a first one-way valve, and the corrugated pipe is connected with an atomizing cover; the atomizing cover is connected with an expiration exhaust opening through a second one-way valve, a first pressure sensor is arranged on the inner side wall of the atomizing cover, a second pressure sensor is arranged in the liquid medicine storing and atomizing cavity, a controller and a power module are arranged in the shell, the controller is connected with the gas compression pump through control switch signals, and the controller is connected with the first pressure sensor, the first one-way valve and the second pressure sensor in a signal mode. Along with breath of a patient, medicine mist is automatically controlled to be exhausted effectively, the medicine can be fully absorbed and used by the patient, and waste of the treatment medicine is avoided.

Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used in different cancer types and with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.

A novel hemopoietin receptor gene (NR12) was successfully isolated by extracting motifs conserved among the amino acid sequences of known hemopoietin receptors and by using the predicted sequence. The NR12 gene encodes two forms of proteins, a transmembrane type and a soluble type. The expression of the NR12 gene was detected in tissues containing hematopoietic cells. NR12 is a novel hemopoietin receptor molecule involved in the regulation of immune system and hematopoiesis in vivo. Thus, NR12 is useful in the search for novel hematopoietic factors that functionally bind to the NR12 receptor, and in the development of therapeutic drugs for diseases associated with immunity or hematopoiesis.

The invention belongs to the field of drug detection, and particularly relates to a method and a kit for detecting five psychotropic drugs and main metabolites thereof in blood. The five psychotropicdrugs and the main metabolites thereof comprise: olanzapine and demethyl olanzapine, risperidone and 9-hydroxy risperidone, aripiprazole and dehydrogenated aripiprazole, Escitalopram and demethyl citalopram, sertraline and N-demethyl sertraline. Accoridng to the method provided by the invention, a pair of quantitative ion pairs is respectively selected for each detection substance, a relative retention time thereof is used as a qualitative basis, and a standard curve is made by using a standard product for quantification; furthermore, the accuracy and effectiveness of the method are evaluatedfrom quality control of three low, middle and high levels, thereby avoiding distortion of the detection result; and meanwhile, an internal standard working solution is applied to correction, so that matrix effects can be avoided, and accurate quantification is realized. The method provided by the invention has the advantages of simple and rapid operation, high flux and low cost, and can be appliedto the therapeutic drug monitoring of the psychotropic drugs in the clinical work of the psychiatry department.

The present invention relates generally to the field of identification and determination of bioactive amino acid sequences. In particular, the present invention provides method(s) for determining the influence of variation in host genes on selection of microorganisms with particular amino acid variants for the purpose of therapeutic drug or vaccine design or individualisation of such treatment. The invention also provides methods for identifying HLA allele-specific microorganism sequence polymorphisms that result from HLA restriction of antigen-specific cellular immune responses. It also provides diagnostic and therapeutic methodologies that may be used to measure or treat infection by a microorganism or to prevent infection by the microorganism.

The present invention relates to compositions and methods comprising peptides with high mutual affinity that, when attached to a protein, assist the protein to fold into a compact structure. By virtue of its stability and binding, this scaffold extends the activity of any contained protein sequence in the presence of cellular and other proteases. This compact structure may have other included functional sequences, which are superior to linear and less constrained peptides for library screening, building structure-biased peptide libraries, and targeting specific intracellular and extracellular compartments. The compositions of the present invention can be displayed on viral, archaeal, prokaryotic and eukaryotic cell surfaces for library screening, drug screening and display. The methods of the present invention are useful for in vivo screening of intracellular effector proteins that modulate signaling pathways, and for identification of interacting proteins in vitro. Therefore, the present invention can be used as a scaffold for gene therapy, for the isolation of new therapeutic drugs, and has potential utilization value for use as a therapeutic agent in physiological fluids.

The invention provides a polypeptide targeting novel coronavirus COVID-19 and application of the polypeptide. The polypeptide comprises an amino acid sequence shown as SEQ ID NO: 1-28; or the polypeptide is a molecule which is obtained by adding 1-20 amino acid polypeptide sequences and / or conjugation connection carbon chains to the N end and / or the C end of SEQ ID NO: 1-28 and has the activity oftargeting coronavirus COVID-19. The polypeptide library is synthesized by adopting a combined chemical method of one bead and one compound (one-by-one-complex, OBOC), so that the polypeptide libraryis obtained. By utilizing the polypeptide library and the S protein on the surface of the novel coronavirus, the screened polypeptide has strong binding capacity with the S protein of the coronavirusCOVID-19, and a basis is provided for research and development of novel coronavirus detection reagents and treatment drugs.

The invention relates to a hyaluronic acid-nano silver-based dressing and a preparation method thereof. The hyaluronic acid-nano silver-based dressing comprises therapeutic drugs, nano silver, hyaluronic acid and degradable synthetic high polymers. The method mainly utilizes an electrostatic spinning technique to proportionally mix a solution containing nano silver and hyaluronic acid with a solution containing therapeutic drugs and synthetic high polymers and process the nano fiber nonwoven fabric. The obtained hyaluronic acid-nano silver-based dressing has the characteristics of favorable uniformity, high porosity, favorable air permeability and favorable biocompatibility. In the hyaluronic acid-nano silver-based dressing preparation process, water is used as the solvent, so no organic solvent residue exists. The method has the advantage of simple technique and low cost. The prepared hyaluronic acid-nano silver-based dressing has wide application range, and can be used for various surgical cuts, burn and scald surfaces, various traumatic wound surfaces, peripheral ulcer surfaces and various non-healing chronic ulcer wound surfaces.

A current system allows data-driven hypothesis generation to identify therapeutic candidates for a disease phenotype treatment by identifying drugs and clinical indications associated with lower occurrences of disease-associated phenotype(s) by a drug / drug class. A current system may include a pharmaceutical hierarchical ontology; a phenotype hierarchical ontology; a record database comprising clinical event records; a database mining engine; and a mapping engine. The database mining engine may iteratively progress through a portion of the pharmacological hierarchical ontology and phenotype hierarchical ontology to iteratively select pairs of cohort entries from each ontology; and for each pair of cohort entries, query the clinical record database for matching records. The mapping engine may map each pair of cohort entries into a matrix comprising a drug-event cell for each pair and apply a value thereto representing the number of database records matching items returned by the database mining engine for the corresponding cohort entries.

The present invention is directed to systems and methods for diagnosing tissue abnormality or diseases, determining effective drug dosages, and monitoring therapeutic drug treatments. The methods and systems described utilize tissue imaging in situ and computer modeling.

The invention designs antimicrobial peptide with drug-resistance bacteria resistance activity and a novel structure. The antimicrobial peptide is obtained by modifying amino acid at N tail ends of natural antimicrobial peptide Anoplin and MPI respectively, then performing acetylization on the amino acid, and performing intermolecular connection on every two side chains of the peptide by replacing a -1H-1,2,3-triazole structure by one 1,4- under the 1,3-dipolar cycloaddition reaction of the click chemistry. The antimicrobial experiments and pyridinium iodide dyeing method experiments for staphylococcus aureus and escherichia coli of the conventional gram-positive bacterium and clinically separated drug-resistant staphylococcus aureus and drug-resistant escherichia coli show that the J-AM peptide and the J-AA peptide which are synthesized by the method are higher in antimicrobial activity, higher in drug-resistance bacteria resistance activity and higher in cytomembrane film penetration capacity and has an obvious drug-resistance advantage of avoiding a drug-resistance phenomenon caused by the general antibiotics; and therefore, the antimicrobial peptide has an extremely high application prospect in preparation of clinical treatment medicines.

The invention discloses traditional Chinese medicine composition for treating oral ulcer, belongs to the field of traditional Chinese medicine, and aims at overcoming the defect that chemotherapeutic drugs for treating the oral ulcer are high in hepatotoxicity at present. The traditional Chinese medicine composition for preventing or treating the oral ulcer comprises the raw materials in parts by weight as follows: 12-16 parts of scutellaria baicalensis, 5-8 parts of honeysuckle, 8-12 parts of pericarpium granati, 8-12 parts of calyx seu fructus physalis, 8-12 parts of radix asparagi, 18-22 parts of dandelion, 18-22 parts of cicada slough, 8-12 parts of lotus leaves, 5-8 parts of radix paeoniae alba, 5-8 parts of mint, 12-16 parts of underleaf pearl, 5-8 parts of fructus arctii, 8-12 parts of goldthread, 8-12 parts of liquorice, 8-12 parts of pseudo-ginseng, 18-22 parts of hawthorn, 8-12 parts of roots of Chinese thorowax, 5-8 parts of roots of red-rooted salvia, 5-8 parts of Chinese gall, 8-12 parts of rhizome of oriental water plantain and 28-32 parts of rhizoma atractylodis. The traditional Chinese medicine composition has a good treatment effect in treating the oral ulcer and obvious clinical promotion values.

The invention belongs to a novel pulmonary artery hypertension treatment drug screening technology established by applying a stem cell technology; with a BMP signal downstream key gene Id1 as a target spot, a double-report-gene original is designed and inserted into an Id1 genome to construct a restructuring carrier, the carrier is transferred into a human embryonic stem cell strain, and a stable-expression CGMCC11091 cell strain is obtained; the CGMCC11091 cell strain is stimulated by a to-be-tested anti pulmonary artery hypertension compound, then cells are cracked by a cell cracking fluid, according to a genetic testing system, the method detects luciferase expression activity, with the Id1 promoter driven double-report-gene expression quantity as an indicator, and a pulmonary artery hypertension treating compound screening model having Id1 expression up-regulated is obtained. The invention also discloses an application of the model in screening regulators for up-regulation of bone morphogenetic protein (BMP) signals, regulators for up-regulation of expression level of BMP-2 acceptors, preparations for improving the pulmonary artery blood hemodynamics, preparations for improving pulmonary vascular reconstitution, pulmonary artery hypertension treatment drugs and cardiopulmonary vascular disease treatment drugs.

The invention discloses a Tribonema sp. PD2 strain with a preservation number of CGMCC No.10488, and application thereof in the production of biodiesel, palmitoleic acid, feed, food, skin care products, and therapeutic drugs for cardiovascular and cerebrovascular diseases, and in the carbon dioxide emission reduction, and waste gas treatment and / or wastewater treatment. The Tribonema sp. PD2 strain has the advantages of fast growth, high biomass and easiness in harvesting, and is suitable for industrial application. The oil content of the Tribonema sp. PD2 strain is as much as 60% or more of the dry biomass, wherein the content of C16-C18 is as much as 85% of the total fatty acids, the content of the palmitoleic acid (C16:1omega7) is no less than 45% of the total fatty acids, and the content of the total unsaturated fatty acids is as much as 65% of the total fatty acids. Therefore the Tribonema sp. PD2 strain is especially suitable for the production of biodiesel and the development of health care products and foods.